Table 2 Therapeutic management of COPD prior to initiating fluticasone/salmeterol
GPs | N patients (n = 352) | Pulmonologists | N patients (n = 358) | |
|---|---|---|---|---|
General care, N (%) 1 | ||||
Consultation with GP | 320 (91.4%) | 350 | 251 (73.6%) | 341 |
Consultation with specialist | 173 (49.6%) | 349 | 215 (60.6%) | 355 |
Emergency visits | 31 (8.9%) | 348 | 53 (14.9%) | 356 |
Hospitalizations | 38 (10.9%) | 350 | 71 (19.8%) | 358 |
Oral corticosteroids | 220 (63.0%) | 349 | 120 (33.7%) | 356 |
Antibiotics | 289 (83.5%) | 346 | 194 (54.6%) | 355 |
Vaccination, N (%) | ||||
Flu1 | 264 (75.4%) | 350 | 214 (60.1%) | 355 |
Pneumococcus (within 5 years) | 168 (48.1%) | 349 | 106 (30.1%) | 352 |
Prior medication, N (%) | 2682 | 2392 | ||
Short-acting bronchodilator | 37 (13.8%) | 26 (10.9%) | ||
Long-acting ± short-acting bronchodilator | 57 (21.3%) | 88 (36.9%) | ||
ICS + long-acting bronchodilator | 87 (32.5%) | 92 (38.5%) | ||
ICS ± short-acting bronchodilator | 57 (21.3%) | 23 (9.6%) | ||
Other ICS combination | 15 (5.6%) | 6 (2.5%) | ||
Other | 15 (5.6%) | 4 (1.6%) | ||
Concomitant medication, N (%) 3 | 1674 | 2584 | ||
Long-acting anticholinergic ± short-acting bronchodilator | 53 (31.7%) | 173 (67.1%) | ||
Short-acting bronchodilator | 81 (48.5%) | 71 (27.5%) | ||
Long-acting β-2 adrenergic agonist | 18 (10.8%) | 11 (4.3%) | ||
Other ICS | 15 (9.0%) | 3 (1.2%) |